Calciscon delivers breakthrough
Diagnostics for Calciprotein
Particles (CPP), potent drivers
of inflammation in multiple
chronic diseases.
Diagnostics for Calciprotein
Particles (CPP), potent drivers
of inflammation in multiple
chronic diseases.
COMPANY
CALCISCON is the world leader in the
development of methods to measure
Calciprotein Particles (CPP) and in
their translation into new products for
clinical use. Calciscon offers the most
comprehensive panel of measurement
methods relative to CPP.
development of methods to measure
Calciprotein Particles (CPP) and in
their translation into new products for
clinical use. Calciscon offers the most
comprehensive panel of measurement
methods relative to CPP.
SCIENCE
Calciprotein Particles (CPP) are a recently discovered class of circulating species recognized
as potent endogenous drivers of inflammation, oxidative stress and calcification.
as potent endogenous drivers of inflammation, oxidative stress and calcification.
For example Calciprotein Particles are crucially involved in the progression of chronic kidney
disease (CKD), and its resulting cardiovascular morbidity and mortality.
Calciscon is initially launching the T50 Calciprotein Crystallization test (T50® test) to
improve the quality of life of patients suffering from end-stage kidney disease.
disease (CKD), and its resulting cardiovascular morbidity and mortality.
Calciscon is initially launching the T50 Calciprotein Crystallization test (T50® test) to
improve the quality of life of patients suffering from end-stage kidney disease.
PRODUCTS
Further products are under development.
Based on our unique expertise, expansion towards therapeutics is planned.
Based on our unique expertise, expansion towards therapeutics is planned.
TEAM
CEO
Vincent Linder, Ph.D.
Serial Entrepreneur in IVD (USA and Europe),
product dev. (CE & FDA), exit (M&A)
Vincent Linder, Ph.D.
Serial Entrepreneur in IVD (USA and Europe),
product dev. (CE & FDA), exit (M&A)
FOUNDER, PRESIDENT, CMO
PROF Andreas Pasch, MD
Scientist and Practicing Nephrologist; Inventor
of the T50 test; Expert in clinical use of T50/CPP
PROF Andreas Pasch, MD
Scientist and Practicing Nephrologist; Inventor
of the T50 test; Expert in clinical use of T50/CPP
Non-Executive Director
Chan-Yuan Lu
10+ year of global expertise in the
VC industry (USA, Taiwan, Europe)
Chan-Yuan Lu
10+ year of global expertise in the
VC industry (USA, Taiwan, Europe)
Non-Executive Director
Karsten Uhlmann
Managing owner of
international brewing group
and senior entrepreneur
Karsten Uhlmann
Managing owner of
international brewing group
and senior entrepreneur
ADVISOR
PROF Edward Smith, PH.D.
Inventor of CPP assay,
Expert in CPP biology
PROF Edward Smith, PH.D.
Inventor of CPP assay,
Expert in CPP biology
ADVISOR
Didier Falconnet, PH.D.
Past Director IVD at GSK, and Previous R&D
leader in 2 startups (with 1 IPO)
Didier Falconnet, PH.D.
Past Director IVD at GSK, and Previous R&D
leader in 2 startups (with 1 IPO)
Head of the Laboratory
SANDRA DE LA ROSA
SANDRA DE LA ROSA
Executive Assistant
& People Officer
ELZA NOVAIS
& People Officer
ELZA NOVAIS
NEWS
04.2024
02.2024
06.2023
05.2023
01.2023
CONTACT
Please contact us. We look forward to hearing from you.
CALCISCON AG
Aarbergstrasse 46,
2503 Biel/Bienne | Switzerland
Phone: +41 32 530 88 60
Email: info@calciscon.com
